Gland Pharma Publishes Newspaper Notice for Member Communication
Gland Pharma Limited published a notice on June 10, 2026, in English and Telugu newspapers as per SEBI regulations. Shareholders are urged to update their email addresses for electronic communication of statutory information. This applies to physical shareholdings via the RTA and dematerialized holdings via Depository Participants.
This is a standard regulatory compliance announcement and does not directly impact the company's operations, financials, or stock performance.
The announcement is a routine regulatory filing regarding newspaper publication for member communication and does not contain any material financial or business developments.
Gland Pharma Limited has announced the publication of a notice in English and Telugu newspapers regarding communication with its members. The notice, titled “Notice for attention of members of Gland Pharma Limited”, is in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company is requesting shareholders who have not yet registered or updated their email addresses to do so. This is to facilitate the sending of communications, including notices for General Meetings, Postal Ballots, Annual Reports, and other statutory information, in electronic form.
Shareholders holding shares in physical mode are asked to register or update their email addresses with MUFG Inline India Private Limited (formerly Link Intime India Private Limited), the Company's Registrar and Transfer Agent. This can be done by sending an email to mt.helpdesk@in.mufg.com or to the company at investors@glandpharma.com, along with their Folio Number and a valid email address.
Members holding shares in dematerialized mode are advised to register or update their email addresses with their respective Depository Participants where their demat accounts are maintained. The notice was published on June 10, 2026, and the request for updating details was dated June 09, 2026.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.